Literature DB >> 15013937

A review of the Vaccine Adverse Event Reporting System database.

David A Geier1, Mark R Geier.   

Abstract

The Vaccine Adverse Event Reporting System (VAERS) is an epidemiological database that has been maintained by the FDA and Centers for Disease Control and Prevention (CDC) since 1990. Authors from the National Immunization Programme of the CDC have previously described an epidemiological technique to make qualitative and quantitative measurement in the VAERS database. Application of this technique by ourselves (with further refinements and additions) have resulted in numerous publications showing the VAERS database has good positive predictive value in evaluating vaccine safety concerns that are compatible with observations by many other authors who have analysed different databases. In conclusion, VAERS studies will be particularly critical in the evaluation of the safety of many new or radically changed vaccines expected to be introduced in the relative near future.

Mesh:

Substances:

Year:  2004        PMID: 15013937     DOI: 10.1517/14656566.5.3.691

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

1.  A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States.

Authors:  David A Geier; Brian S Hooker; Janet K Kern; Paul G King; Lisa K Sykes; Mark R Geier
Journal:  Transl Neurodegener       Date:  2013-12-19       Impact factor: 8.014

2.  Harms in Systematic Reviews Paper 1: An introduction to research on harms.

Authors:  Riaz Qureshi; Evan Mayo-Wilson; Tianjing Li
Journal:  J Clin Epidemiol       Date:  2021-11-03       Impact factor: 7.407

3.  The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS).

Authors:  David A Geier; Paul G King; Lisa K Sykes; Mark R Geier
Journal:  Med Sci Monit       Date:  2012-02

4.  Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010.

Authors:  G S Goldman; N Z Miller
Journal:  Hum Exp Toxicol       Date:  2012-04-24       Impact factor: 2.903

5.  A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.

Authors:  David A Geier; Mark R Geier
Journal:  Clin Rheumatol       Date:  2014-12-23       Impact factor: 2.980

6.  Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study.

Authors:  David A Geier; Janet K Kern; Brian S Hooker; Paul G King; Lisa K Sykes; Kristin G Homme; Mark R Geier
Journal:  Interdiscip Toxicol       Date:  2015-06

7.  Abnormal Brain Connectivity Spectrum Disorders Following Thimerosal Administration: A Prospective Longitudinal Case-Control Assessment of Medical Records in the Vaccine Safety Datalink.

Authors:  David A Geier; Janet K Kern; Kristin G Homme; Mark R Geier
Journal:  Dose Response       Date:  2017-03-16       Impact factor: 2.658

8.  Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.

Authors:  David A Geier; Mark R Geier
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalink.

Authors:  David A Geier; Janet K Kern; Brian S Hooker; Paul G King; Lisa K Sykes; Mark R Geier
Journal:  N Am J Med Sci       Date:  2014-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.